Identification of preexisting adaptive immunity to Cas9 proteins in humans.

Published on Jan 28, 2019in Nature Medicine30.641
· DOI :10.1038/S41591-018-0326-X
Carsten T. Charlesworth3
Estimated H-index: 3
(Stanford University),
Priyanka S. Deshpande2
Estimated H-index: 2
(Stanford University)
+ 17 AuthorsMatthew H. Porteus49
Estimated H-index: 49
(Stanford University)
The CRISPR–Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR–Cas9 system to therapeutically correct human genetic diseases1–6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes5,7. Given that these two bacterial species infect the human population at high frequencies8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR–Cas9 system moves toward clinical trials.
  • References (41)
  • Citations (121)
📖 Papers frequently viewed together
11 Authors (Le Cong, ..., Feng Zhang)
8,020 Citations
7 Authors (Lei S. Qi, ..., Wendell A. Lim)
2,343 Citations
12 Authors (Bernd Zetsche, ..., Feng Zhang)
1,622 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Dimitrios L. Wagner (Charité)H-Index: 3
#2Leila Amini (Charité)H-Index: 3
Last. Michael Schmueck-Henneresse (Charité)H-Index: 5
view all 8 authors...
The discovery of the highly efficient site-specific nuclease system CRISPR–Cas9 from Streptococcus pyogenes has galvanized the field of gene therapy1,2. The immunogenicity of Cas9 nuclease has been demonstrated in mice3,4. Preexisting immunity against therapeutic gene vectors or their cargo can decrease the efficacy of a potentially curative treatment and may pose significant safety issues3–6. S. pyogenes is a common cause for infectious diseases in humans, but it remains unclear whether it indu...
73 CitationsSource
#1Vijaya L. Simhadri (CBER: Center for Biologics Evaluation and Research)H-Index: 10
#2Joseph R. McGill (CBER: Center for Biologics Evaluation and Research)H-Index: 4
Last. Zuben E. Sauna (CBER: Center for Biologics Evaluation and Research)H-Index: 37
view all 6 authors...
The repurposing of the CRISPR/Cas microbial adaptive immune system for gene editing has resulted in an exponential rise in new technologies and promising approaches for treating numerous human diseases. While some of the approaches being currently developed involve ex vivo editing by CRISPR/Cas9, many more potential applications will require in vivo editing. The in vivo use of this technology comes with challenges, one of which is the immune response to Cas9, a protein of microbial origin. Thus,...
50 CitationsSource
#1Jonathan D. FinnH-Index: 1
#2Amy Rhoden SmithH-Index: 4
Last. David V. MorrisseyH-Index: 11
view all 23 authors...
Summary The development of clinically viable delivery methods presents one of the greatest challenges in the therapeutic application of CRISPR/Cas9 mediated genome editing. Here, we report the development of a lipid nanoparticle (LNP)-mediated delivery system that, with a single administration, enabled significant editing of the mouse transthyretin ( Ttr ) gene in the liver, with a >97% reduction in serum protein levels that persisted for at least 12 months. These results were achieved with an L...
120 CitationsSource
#1Carsten T. Charlesworth (Stanford University)H-Index: 3
#2Priyanka S. Deshpande (Stanford University)H-Index: 2
Last. Matthew H. Porteus (Stanford University)H-Index: 49
view all 10 authors...
The CRISPR-Cas9 system has proven to be a powerful tool for genome editing allowing for the precise modification of specific DNA sequences within a cell. Many efforts are currently underway to use the CRISPR-Cas9 system for the therapeutic correction of human genetic diseases. The most widely used homologs of the Cas9 protein are derived from the bacteria Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes). Based on the fact that these two bacterial species cause infection...
74 CitationsSource
#1Tom Ford (International AIDS Vaccine Initiative)H-Index: 1
#2Claire Wenden (International AIDS Vaccine Initiative)H-Index: 1
Last. Katie J. Ewer (University of Oxford)H-Index: 33
view all 10 authors...
Ex vivo functional immunoassays such as ELISpot and intracellular cytokine staining (ICS) by flow cytometry are crucial tools in vaccine development both in the identification of novel immunogenic targets and in the immunological assessment of samples from clinical trials. Cryopreservation and subsequent thawing of PBMCs via validated processes has become a mainstay of clinical trials due to processing restrictions inherent in the disparate location and capacity of trial centres, and also in the...
10 CitationsSource
#1Justin Eyquem (Kettering University)H-Index: 9
#2Jorge Mansilla-Soto (Kettering University)H-Index: 10
Last. Michel Sadelain (Kettering University)H-Index: 79
view all 9 authors...
Introducing chimeric antigen receptors into the endogenous T-cell receptor locus reduces tonic signalling, averts accelerated T-cell differentiation and delays T-cell exhaustion, leading to enhanced function and anti-tumour efficacy compared to random integrations.
454 CitationsSource
#1Daniel P. Dever (Stanford University)H-Index: 14
#2Rasmus O. Bak (Stanford University)H-Index: 21
Last. Matthew H. PorteusH-Index: 49
view all 16 authors...
These preclinical studies outline a CRISPR-based methodology for correcting β-globin gene mutations in haematopoietic stem cells to advance the development of next-generation therapies for β-haemoglobinopathies.
316 CitationsSource
#1Keiichiro Suzuki (Salk Institute for Biological Studies)H-Index: 41
#2Yuji TsunekawaH-Index: 8
view all 35 authors...
A method for CRISPR-based genome editing that harnesses cellular non-homologous end joining activity to achieve targeted DNA knock-in in non-dividing tissues.
418 CitationsSource
#1Mark A. DeWitt (University of California, Berkeley)H-Index: 11
#2Wendy Magis (Children's Hospital Oakland Research Institute)H-Index: 4
Last. Jacob E. Corn (University of California, Berkeley)H-Index: 34
view all 15 authors...
Sickle cell disease is a genetic disorder caused by a mutation in one of the hemoglobin genes, which causes deformation of red blood cells and results in occlusion of blood vessels, severe pain crises, and progressive organ injury. To correct the mutation that causes this disease, DeWitt et al . modified hematopoietic stem cells from sickle cell disease patients using a CRISPR/Cas9 gene editing approach. The authors showed that the corrected cells successfully engrafted in a mouse model and prod...
197 CitationsSource
#1Wei Leong Chew (Harvard University)H-Index: 8
#2Mohammadsharif Tabebordbar (Harvard University)H-Index: 9
Last. George M. Church (Wyss Institute for Biologically Inspired Engineering)H-Index: 144
view all 9 authors...
Packaging split Cas9 into AAVs increases cargo capacity and allows for efficient genome editing and gene activation in vivo. AAV–split-Cas9 activates the host immune system but does not trigger the extensive cellular damage observed with delivery of Cas9 via DNA electroporation.
221 CitationsSource
Cited By121
#1Maryam Mehravar (Shahid Beheshti University of Medical Sciences and Health Services)
#2Elham Roshandel (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 2
Last. Abbas Hajifathali (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 8
view all 7 authors...
Abstract The ability to change the genetic information of immune cells is a powerful tool for basic and clinical settings. CRISPR/Cas9 gene editing technology by providing an efficient approach has accelerated immune cell therapy of cancers. Lymphoid cancers comprise a wide array of disease including lymphoma, multiple myeloma and lymphocytic leukemia. Here, we review therapeutic applications of the CRISPR/Cas9 technology for immune cell therapy of common lymphoid malignancies. We describe curre...
#1Jamie Fitzgerald (HFH: Henry Ford Hospital)H-Index: 3
The ability to edit DNA at the nucleotide level using clustered regularly interspaced short palindromic repeats (CRISPR) systems is a relatively new investigative tool that is revolutionizing the analysis of many aspects of human health and disease, including orthopaedic disease. CRISPR, adapted for mammalian cell genome editing from a bacterial defence system, has been shown to be a flexible, programmable, scalable, and easy-to-use gene editing tool. Recent improvements increase the functionali...
#1Joost van Haasteren (California Institute for Quantitative Biosciences)
#2Jie Li (University of California, Berkeley)H-Index: 7
Last. David V. SchafferH-Index: 64
view all 5 authors...
Genome editing has the potential to treat an extensive range of incurable monogenic and complex diseases. In particular, advances in sequence-specific nuclease technologies have dramatically accelerated the development of therapeutic genome editing strategies that are based on either the knockout of disease-causing genes or the repair of endogenous mutated genes. These technologies are progressing into human clinical trials. However, challenges remain before the therapeutic potential of genome e...
#1Yuan Zhang (Stanford University)
#2Ioannis Karakikes (Stanford University)H-Index: 28
view all 2 authors...
Abstract The growing appreciation of human genetics and genomics in cardiovascular disease (CVD) accompanied by the technological breakthroughs in genome editing, particularly the CRISPR-Cas9 technologies, has presented an unprecedented opportunity to explore the application of genome editing tools in cardiovascular medicine. The ever-growing genome-editing toolbox includes an assortment of CRISPR-Cas systems with increasing efficiency, precision, flexibility, and targeting capacity. Over the pa...
#1Ramon Arens (LEI: Leiden University)H-Index: 5
#1Ramon ArensH-Index: 31
Last. Ferenc A. Scheeren (LEI: Leiden University)
view all 2 authors...
Inhibitory and stimulatory immune checkpoint molecules play important roles in regulating immune responses. An increasing number of these immune regulators are currently being evaluated as targets in putative anti-cancer therapies. Recently, sophisticated genetic screens have been performed to increase our understanding of immune checkpoint pathways and their immunomodulatory regulators. Here, we summarize novel insights obtained by these screens and discuss new directions to advance possible st...
#1Wenhan Yu (NIH: National Institutes of Health)
#2Zhijian Wu (NIH: National Institutes of Health)
Abstract A variety of inherited or multifactorial ocular diseases call for novel treatment paradigms. The newly developed genome editing technology, CRISPR, has shown great promise in treating these diseases, but delivery of the CRISPR/Cas components to target ocular tissues and cells requires appropriate use of vectors and routes of administration to ensure safety, efficacy and specificity. Although adeno-associated viral (AAV) vectors are thus far the most commonly used tool for ocular gene de...
#1Davide Pietro Cinà (UBC: University of British Columbia)
#2Drew Phillips (UBC: University of British Columbia)
Last. Ryan Flannigan (UBC: University of British Columbia)H-Index: 8
view all 3 authors...
Male factor infertility is common and often multifactorial. A subset of these patients have underlying genetic etiologies. CRISPR/Cas9 is a simple and flexible gene editing tool with promising applications in this space. This review aims to summarize the advances that CRISPR/Cas9-based tools have brought to the field and propose future directions for study. CRISPR/Cas9 has been applied successfully to spermatogonial stem cells (SSCs) and via pronuclear injection of zygotes to generate animal mod...
#1Olivier Humbert (Fred Hutchinson Cancer Research Center)H-Index: 11
#2Clare Samuelson (Fred Hutchinson Cancer Research Center)H-Index: 1
Last. Hans-Peter Kiem (UW: University of Washington)H-Index: 17
view all 3 authors...
Genome editing therapies represent a significant advancement in next-generation, precision medicine for the management of haematological diseases, and CRISPR/Cas9 has to date been the most successful implementation platform. From discovery in bacteria and archaea over three decades ago, through intensive basic research and pre-clinical development phases involving the modification of therapeutically relevant cell types, CRISPR/Cas9 genome editing is now being investigated in ongoing clinic trial...
#1Lydia Teboul (Medical Research Council)H-Index: 25
#2Yann Herault (UDS: University of Strasbourg)H-Index: 37
Last. Guillaume Pavlovic (UDS: University of Strasbourg)H-Index: 13
view all 5 authors...
Abstract Genome editing tools have already revolutionised biomedical research and are also expected to have an important impact in the clinic. However, their extensive use in research has revealed much unpredictability, both off- and on-target, in the outcome of their application. We discuss the challenges associated with this unpredictability, both for research and in the clinic. For the former, an extensive validation of the model is essential. For the latter, potential unpredicted activity do...
1 CitationsSource
#1Ang Li (Rice University)H-Index: 3
#2Mark R. Tanner (BCM: Baylor College of Medicine)H-Index: 10
Last. Christine Beeton (BCM: Baylor College of Medicine)H-Index: 29
view all 11 authors...
Abstract Adeno-Associated Viral (AAV) vectors are a leading candidate for the delivery of CRISPR/Cas9 for therapeutic genome editing in vivo. However, AAV-based delivery involves persistent expression of the Cas9 nuclease, a bacterial protein. Recent studies indicate a high prevalence of neutralizing antibodies and T-cells specific to the commonly used Cas9 orthologs from Streptococcus pyogenes (SpCas9) and Staphylococcus aureus (SaCas9) in humans. We tested in a mouse model whether pre-existing...
4 CitationsSource